Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose

International Journal of Clinical Practice

Volumn 67, Issue 4, 2013, Pages 297-302

  Sazonov, V ^a   MacCubbin, D ^a   Sisk, C McCrary ^a   Canner, P L ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Trials & Surveys Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; NICOTINIC ACID; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME;

BLOOD GLUCOSE; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FASTING; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NIACIN;

EID: 84875540714     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12089     Document Type: Article

References (10)

1. Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106: 3140-141.
2. Guyton JR, Goldberg AC, Kreisberg RA, et al., Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82: 737-43.
3. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81.
4. Canner PL, Furberg CD, Terrin ML, McGovern ME,. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005; 95: 254-7.
5. Canner PL, Furberg CD, McGovern ME,. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006; 97: 477-9.
6. McGovern ME,. Use of nicotinic acid in patients with elevated fasting glucose, diabetes or metabolic syndrome. Br J Diabetes Vasc Dis 2004; 4: 78-85.
7. Garg A, Grundy SM,. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264: 723-6.
8. Garg A, Grundy SM,. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13: 153-69.
9. Elam MB, Hunninghake DB, Davis KB, et al., Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA 2000; 284: 1263-70.
10. Grundy SM, Vega GL, McGovern ME, et al., Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 2002; 162: 1568-76.